Gen-Probe Incorporated Rating Lowered to Neutral at Robert W. Baird (GPRO)

By admin | 6 years ago

Gen-Probe Incorporated (NASDAQ: GPRO) was downgraded by investment analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a note issued to investors on Friday. They currently have a $83.00 target price on the stock.

Shares of Gen-Probe Incorporated traded up 0.20% during mid-day trading on Friday, hitting $81.29. Gen-Probe Incorporated has a one year low of $53.92 and a one year high of $86.96. The company has a market cap of $3.668 billion and a P/E ratio of 78.69.

Gen-Probe Incorporated last issued its quarterly earnings data on Monday, April 30th. The company reported $0.55 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.51 by $0.04. Gen-Probe Incorporated’s revenue was up 7.3% compared to the same quarter last year. On average, analysts predict that Gen-Probe Incorporated will post $0.67 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at RBC Capital (NYSE: RY) downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “sector perform” rating in a research note to investors on Tuesday, May 1st. They now have a $82.75 price target on the stock, up previously from $72.00. Separately, analysts at ThinkEquity downgraded shares of Gen-Probe Incorporated from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, May 1st. Finally, analysts at Raymond James (NYSE: RJF) downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, May 1st.

Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing molecular diagnostic products and services, which are used to diagnose human diseases, screen donated human blood, and ensures transplant compatibility.

About the author